Cardiovascular Systems (Nasdaq: CSII) is expected to report Q1 earnings on Oct. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cardiovascular Systems's revenues will grow 15.6% and EPS will remain in the red.
The average estimate for revenue is $21.6 million. On the bottom line, the average EPS estimate is -$0.33.
Revenue details
Last quarter, Cardiovascular Systems reported revenue of $22.9 million. GAAP reported sales were 5.5% higher than the prior-year quarter's $21.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at -$0.24. GAAP EPS were -$0.24 for Q4 compared to -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 77.4%, 320 basis points worse than the prior-year quarter. Operating margin was -17.4%, 1,550 basis points worse than the prior-year quarter. Net margin was -20.1%, 870 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $93.8 million. The average EPS estimate is -$1.15.
Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cardiovascular Systems is buy, with an average price target of $15.10.
- Add Cardiovascular Systems to My Watchlist.
